Profile data is unavailable for this security.
About the company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
- Revenue in SEK (TTM)721.00k
- Net income in SEK-37.07m
- Incorporated2008
- Employees3.00
- LocationIsofol Medical AB (publ)Biotech Center, Arvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317972280
- Fax+46 317411701
- Websitehttps://isofolmedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sprint Bioscience AB | 50.49m | -441.00k | 94.96m | 28.00 | -- | 3.42 | 13,565.05 | 1.88 | -0.0064 | -0.0064 | 0.7232 | 0.3978 | 1.01 | -- | 7.58 | 1,803,036.00 | -0.8838 | -71.22 | -1.58 | -113.71 | 82.77 | 62.75 | -0.8735 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Immunovia AB (publ) | 1.58m | -309.44m | 95.10m | 11.00 | -- | 1.42 | -- | 60.38 | -8.27 | -8.27 | 0.0412 | 1.48 | 0.0079 | 74.81 | 7.89 | 143,181.80 | -155.00 | -41.33 | -179.24 | -44.24 | -4,687.68 | -7,553.76 | -19,646.92 | -20,879.26 | 2.69 | -22.84 | 0.1329 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| Biosergen AB | 0.00 | -27.04m | 96.86m | 3.00 | -- | 8.36 | -- | -- | -0.4007 | -0.4007 | 0.00 | 0.0418 | 0.00 | -- | -- | 0.00 | -131.31 | -- | -217.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.25 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -46.41m | 97.04m | 4.00 | -- | 15.29 | -- | -- | -0.1887 | -0.1887 | 0.00 | 0.0183 | 0.00 | -- | -- | 0.00 | -256.08 | -125.42 | -351.79 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Toleranzia AB | 0.00 | -7.46m | 98.54m | -- | -- | 0.6419 | -- | -- | -0.0597 | -0.0597 | 0.00 | 0.779 | 0.00 | -- | -- | -- | -5.21 | -7.45 | -5.43 | -7.78 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Ziccum AB | 3.75m | -21.41m | 100.32m | 8.00 | -- | 10.56 | -- | 26.77 | -1.54 | -1.54 | 0.2701 | 0.6191 | 0.1553 | -- | 2.01 | 468,375.00 | -88.74 | -68.51 | -109.73 | -76.47 | -- | -- | -571.44 | -2,598.03 | -- | -- | 0.0908 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| Wntresearch AB | 0.00 | -32.47m | 103.49m | 2.00 | -- | 0.6516 | -- | -- | -0.1108 | -0.1108 | 0.00 | 0.1834 | 0.00 | -- | -- | -- | -134.87 | -100.71 | -166.68 | -123.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -5.65 | -- | -- | -- |
| Bio-Works Technologies AB | 43.90m | -56.82m | 107.58m | 38.00 | -- | 2.44 | -- | 2.45 | -1.58 | -1.58 | 1.22 | 1.13 | 0.571 | 1.82 | 5.83 | 1,155,158.00 | -73.91 | -49.14 | -101.72 | -57.90 | 61.10 | 69.88 | -129.44 | -168.30 | 2.79 | -- | 0.00 | -- | 6.23 | 46.24 | -26.41 | -- | 1.95 | -- |
| Isofol Medical AB (publ) | 721.00k | -37.07m | 111.77m | 3.00 | -- | 0.9204 | -- | 155.02 | -0.233 | -0.233 | 0.0045 | 0.7518 | 0.0041 | -- | 0.0728 | 240,333.30 | -21.15 | -66.73 | -26.32 | -88.27 | -4,773.37 | -- | -5,141.61 | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Opticept Technologies AB | 9.15m | -80.36m | 112.27m | 29.00 | -- | 0.3052 | -- | 12.28 | -2.51 | -2.51 | 0.2844 | 8.72 | 0.0213 | -0.0638 | 2.37 | 315,344.80 | -18.69 | -41.76 | -21.18 | -46.20 | 125.88 | 62.65 | -879.64 | -882.41 | 0.6216 | -14.16 | 0.0566 | -- | -12.90 | 49.17 | 19.80 | -- | 45.22 | -- |
| New Nordic Healthbrands AB | 533.85m | -6.20m | 123.28m | 73.00 | -- | 1.16 | -- | 0.2309 | -1.00 | -1.00 | 86.17 | 17.11 | 2.13 | 1.72 | 4.89 | 7,313,014.00 | -2.47 | 5.36 | -5.55 | 10.55 | 65.23 | 67.30 | -1.16 | 2.38 | 0.8906 | -1.15 | 0.2138 | 47.96 | 9.51 | 6.28 | -119.41 | -- | 28.36 | -- |
| SoftOx Solutions AS | 6.91m | -41.65m | 125.64m | -- | -- | -- | -- | 18.19 | -1.98 | -1.98 | 0.3286 | -0.0127 | 0.081 | -- | 1.60 | -- | -48.81 | -50.83 | -82.20 | -64.58 | -- | -- | -602.91 | -646.67 | 0.1745 | -3.45 | -- | -- | -1.88 | 10.06 | 40.85 | -- | 39.43 | -- |
| Bactiquant A/S | 19.20m | -20.45m | 127.97m | -- | -- | 5.69 | -- | 6.67 | -0.6358 | -0.6358 | 0.5971 | 0.6133 | 0.5055 | 3.67 | 2.83 | -- | -53.83 | -41.26 | -62.59 | -47.16 | -6.14 | 12.89 | -106.51 | -71.77 | 5.43 | -8.54 | 0.0431 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Enorama Pharma AB | 1.22m | -43.96m | 129.83m | -- | -- | 5.45 | -- | 106.60 | -2.16 | -2.16 | 0.0423 | 0.4309 | 0.0306 | 1.07 | 0.3212 | -- | -110.45 | -64.94 | -277.27 | -94.45 | -267.08 | 86.49 | -3,609.52 | -405.42 | 0.7249 | -- | 0.023 | -- | -37.96 | 34.20 | -51.50 | -- | -- | -- |
| Biovica International AB | 5.98m | -122.99m | 130.37m | 37.00 | -- | 1.04 | -- | 21.81 | -2.42 | -2.42 | 0.115 | 1.62 | 0.033 | -0.3053 | 8.43 | 170,800.00 | -67.80 | -42.10 | -74.69 | -46.33 | 110.09 | 277.88 | -2,057.41 | -2,149.68 | 7.10 | -- | 0.057 | -- | 65.43 | 4.44 | -84.14 | -- | -20.20 | -- |
| AlzeCure Pharma AB | 0.00 | -37.17m | 130.38m | 11.00 | -- | 5.48 | -- | -- | -0.5986 | -0.5986 | 0.00 | 0.3829 | 0.00 | -- | -- | 0.00 | -72.28 | -52.78 | -88.22 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Isofol Medical AB (publ)'s reporting currency: Swedish Krona SEK
5.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 24 Aug 2022 | 8.29m | 5.13% |
| SEB Investment Management ABas of 28 Mar 2024 | 1.02m | 0.63% |
| Skandia Investment Management ABas of 29 Feb 2024 | 159.45k | 0.10% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
